Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Trainline sales hit record; unveils £75m buyback

(Sharecast News) - Online ticketing platform Trainline said fiscal year sales hit a record of almost £6bn and announced a new £75m share buyback. Total group sales for the year to February rose 13% to £5.9bn, the company said in a trading update on Thursday.

Group adjusted core earnings as a percentage of net ticket sales were expected to be marginally ahead of the company's previously upgraded guidance of around 2.6%. Trainline said it continues to expect adjusted core earnings of between 2.6% and 2.7% of net ticket sales in financial 2026.

The company added that it was talking to the government about its plans to reform the rail industry and impact on the ticketing sector.

Shares in Trainline slumped last month on news that Great British Railway (GBR), the arms-length body that will oversee the UK's railway system, would be able to reform the fares and ticketing system without operators' agreement.

"Trainline will continue to invest for growth in the UK - including increasingly leveraging generative AI ... reflecting that (it) already thrives in a competitive environment in the UK (and) GBR's retailing will likely take several years to crystallise, with the precursory establishment of GBR as a governing body only expected to happen by 2027 at the earliest," the company said.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.